David is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers. David is currently the CEO of ONL Therapeutics based in Ann Arbor, MI. ONL Therapeutics is developing therapeutics based on Fas inhibition to protect the vision of patients with retinal disease. David is the former CEO of Armune BioScience. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017. He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division. David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.